24 Jun - 4 min read

Broad-Based Black Economic Empowerment Act: annual compliance report

Broad-Based Black Economic Empowerment Act: annual compliance report

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, or the “Company”, or the “Group”)

24 June 2021

BROAD-BASED BLACK ECONOMIC EMPOWERMENT ACT: ANNUAL COMPLIANCE REPORT

In accordance with the JSE Limited Listings Requirements, notice is hereby given that the Company’s
annual broad-based black economic empowerment compliance report (“compliance report”) in terms
of section 13G(2) of the South African Broad-Based Black Economic Empowerment Act, No. 53 of 2003,
as amended (the “B-BBEE Act”), has been submitted to the Broad-Based Black Economic
Empowerment Commission (the “B-BBEE Commission”). The compliance report is available on
Mediclinic’s website at mediclinic.com/en/governance/sustainable development.

The compliance report relates to the Group’s South African operations and presents an assessment of
the broad-based black economic empowerment status of Mediclinic International (RF) (Pty) Ltd, a
wholly owned subsidiary of the Company, and its subsidiaries which include Mediclinic Southern Africa
(Pty) Ltd.

About the B-BBEE Act

The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based
black economic empowerment in South Africa and is intended to encourage transformation by including
black people in the economy. It covers aspects such as ownership, management control, skills
development, enterprise and supplier development and socio-economic development. Although
compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is voluntary,
an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which became
effective in June 2016, requiring a public company, listed on the Johannesburg Stock Exchange (“JSE”),
to submit its annual compliance report to the B-BBEE Commission, to load its compliance report on its
website and to publish a SENS announcement confirming the aforementioned steps taken.

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates (“UAE”).

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

At 31 March 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day
case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations
included 50 hospitals (three of which in Namibia), five sub -acute hospitals, two mental health facilities
and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.

The Company’s primary listing is on the London Stock Exchange (“LSE”) in the UK, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 24-06-2021 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

More from Mediclinic International plc


Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Mediclinic International plc (JSE:MEI) when you join Listcorp.